The United States market has shown robust growth, climbing 2.3% in the last week and 25% over the past year, with earnings projected to grow by 19% annually in the coming years. In such a thriving market environment, identifying promising stocks requires a focus on financial stability and growth potential. Penny stocks, though an older term, remain relevant as they often highlight smaller or newer companies that can offer substantial value when backed by strong fundamentals.

Below we spotlight a couple of our favorites from our exclusive screener.

CervoMed (CRVO)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: CervoMed Inc. is a clinical-stage biotechnology company focused on developing and commercializing treatments for age-related neurologic disorders, with a market cap of $22.96 million.

Operations: CervoMed Inc. does not report any revenue segments as it is a clinical-stage biotechnology company.

Market Cap: $22.96M

CervoMed Inc., a clinical-stage biotechnology firm, is pre-revenue with a market cap of US$22.96 million and no long-term liabilities. The company has faced increasing losses over the past five years, averaging 55.5% annually, and has less than a year of cash runway if current free cash flow trends continue. Recent developments include promising Phase 2b trial results for neflamapimod in treating dementia with Lewy bodies (DLB), indicating potential cognitive and functional benefits without Alzheimer's co-pathology. However, the management team lacks experience with an average tenure of 1.7 years, contributing to its volatile stock performance recently.

Codexis (CDXS)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Codexis, Inc. specializes in providing technology solutions for therapeutics manufacturing through its proprietary CodeEvolver technology platform, focusing on the discovery, development, enhancement, and commercialization of novel enzymes across various global regions; the company has a market cap of approximately $224.51 million.

Operations: The company generates $78.09 million in revenue from its biotechnology segment.

Market Cap: $224.51M

Codexis, Inc. is navigating the penny stock landscape with a focus on advancing its ECO Synthesis Manufacturing Platform for RNA therapeutics. The company reported Q1 2026 revenue of US$15.25 million, doubling from the previous year, while reducing net losses to US$8.7 million. Despite being unprofitable and having a negative return on equity of -73.99%, Codexis maintains more cash than total debt and sufficient short-term assets to cover liabilities. Recent advancements in RNA synthesis technology highlight potential industry impact, though challenges remain with an inexperienced board and management team averaging tenures of 2.3 and 1.3 years respectively.

Laird Superfood (LSF)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Laird Superfood, Inc. manufactures and markets plant-based natural and functional foods in the United States with a market cap of $44.25 million.

Operations: The company generates revenue from its Superfood segment, which amounts to $49.89 million.

Market Cap: $44.25M

Laird Superfood, Inc. is navigating the penny stock market with a focus on plant-based natural foods, reporting Q1 2026 sales of US$13.94 million and achieving net income of US$1.75 million, a turnaround from the previous year's loss. Despite being unprofitable over the past five years, Laird has reduced losses by 34% annually and remains debt-free with sufficient short-term assets to cover liabilities. The company recently relaunched its Organic Prebiotic Daily Greens product, emphasizing quality and organic ingredients. While volatility remains high, Laird's management and board are experienced with average tenures of over four years each.

Make It Happen

• Unlock our comprehensive list of 335 US Penny Stocks by clicking here.
• Searching for a Fresh Perspective? Outshine the giants: these 14 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.